SIV DNA VACCINES AND MUCOSAL IMMUNITY

SIV DNA 疫苗和粘膜免疫

• 批准号: 8357900
• 负责人: ANNA ALDOVINI
• 金额: $ 6.84万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357900
• 关键词: AIDS Vaccines; AIDS vaccine development; DNA; DNA Vaccines; Development; Disadvantaged; Funding; Grant; HIV; HIV Infections; Immunologic Deficiency Syndromes; Infection; Mucosal Immunity; National Center for Research Resources; New England; Primates; Principal Investigator; Recombinants; Research; Research Infrastructure; Resources; Route; SIV; Source; United States National Institutes of Health; Vaccination; Vaccines; Vaccinia; Vaccinium; base; cost; transmission process; vaccine candidate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. SIV DNA vaccines and mucosal immunity More than 80% of global transmission of HIV infection occurs via mucosal routes. The ability of vaccines to induce mucosal immunity may be required for protection against HIV infection and the immunodeficiency syndrome that emerges after infection. Various AIDS vaccine candidates are currently under development, each with potential advantages and disadvantages. DNA vaccines have features that make them attractive vaccine candidates for HIV and the combination of DNA vaccination plus recombinant vaccinia is one of the favored approaches in AIDS vaccine development.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 SIV DNA疫苗和粘膜免疫 超过80％的全球艾滋病毒感染传播是通过粘膜路线发生的。 疫苗诱导粘膜免疫的能力可能需要防止HIV感染和感染后出现的免疫缺陷综合症。 各种艾滋病疫苗候选者目前正在开发中，每种疫苗都有潜在的优势和缺点。 DNA疫苗的特征使其具有吸引力的HIV疫苗，而DNA疫苗接种加重组疫苗的组合是AIDS疫苗开发中最受欢迎的方法之一。